1. A control device for starting motion of an own mobile body, said control device comprising:
a distance measuring part for measuring distance to a front going mobile body;
a speed control part for controlling the speed of said own mobile body such that distance to said front going mobile body will be constant based on said measured distance measured by said distance measuring part;
a stop control part for detecting stopping of said front going mobile body based on said measured distance measured by said distance measuring part and generating a stop control signal for said own mobile body based on the detecting of the stopping of said front going mobile body;
a start control part for detecting a start of said front going mobile body based on said measured distance measured by said distance measuring part and generating a start control signal for said own mobile body based on the detecting of the start of said front going mobile body; and
an image-taking device for taking a first group of images of the front of said own mobile body until immediately after said stop control part detects the stopping of said front going mobile body and a second group of images of the front of said own mobile body when said start control part detects the start of said front going mobile body, a first image being selected from said first group of images and a second image being selected from said second group of images;
wherein said start control part serves to inhibit said start control signal by concluding that there is an object in front of said own mobile body if said first image and said second image do not match.
2. The control device of claim 1 wherein said image-taking device serves to take images of the road surface in front of said own mobile body.
3. The control device of claim 1 further comprising an illuminator that illuminates the front of said own mobile body when said image-taking device takes an image of said front of said own mobile body.
4. The control device of claim 1 wherein said image-taking device serves to take a third image of the front of said own mobile body when a specified length of time has passed since said start control signal is inhibited, and wherein said start control part serves to remove the inhibition of said start control signal if said first image and said third image match.
5. The control device of claim 2 wherein said image-taking device serves to take a third image of the front of said own mobile body when a specified length of time has passed since said start control signal is inhibited, and wherein said start control part serves to remove the inhibition of said start control signal if said first image and said third image match.
6. The control device of claim 3 wherein said image-taking device serves to take a third image of the front of said own mobile body when a specified length of time has passed since said start control signal is inhibited, and wherein said start control part serves to remove the inhibition of said start control signal if said first image and said third image match.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the formula I
wherein
Ar1 is selected from a group consisting of:
6- to 10-membered arylene and 5- to 10-membered heteroarylene all of which may be optionally substituted with one or more substituents RA, wherein R1 and RA linked to adjacent C-atoms of Ar1 may be connected with each other and together form a C3-5-alkylene bridging group in which 1, 2 or 3 \u2014CH2\u2014 groups may be replaced by O, C(\u2550O), S, S(\u2550O), S(\u2550O)2, NH or N(C1-4-alkyl)-, wherein the alkylene bridge may optionally be substituted by one or two C1-3-alkyl groups;
RA is selected from a group consisting of:
H, F, Cl, Br, I, CN, OH, \u2014NO2, C2-4-alkenyl, C1-4-alkyl-C(\u2550O)\u2014, H2N\u2014, H2N\u2014C(\u2550O)\u2014, H2N\u2014S(\u2550O)2\u2014, HO\u2014C(\u2550O)\u2014, C1-4-alkyl-O\u2014C(\u2550O)\u2014, phenyl and phenyl-C1-3-alkyl,
wherein in each NH2\u2014 group, one or both hydrogen atoms may independently be replaced by C1-4-alkyl;
wherein each alkyl and cycloalkyl may be optionally substituted with one or more F atoms;
R1 is selected from a group consisting of:
H, OH, C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-O\u2014, C3-7-cycloalkyl-C1-3-alkyl-O\u2014, H2N\u2014, (C1-4-alkyl)NH\u2014, (C1-4-alkyl)2N\u2014, C3-7-cycloalkyl-NH\u2014, C3-7-cycloalkyl-N(C1-4-alkyl)-, C3-7-cycloalkyl-C1-3-alkyl-NH\u2014, (C3-7-cycloalkyl-C1-3-alkyl)-N(C1-4-alkyl)-, C1-4-alkyl-C(\u2550O)\u2014, C1-4-alkyl-S(\u2550O)2\u2014, HO\u2014C(\u2550O)\u2014, C1-4-alkyl-O\u2014C(\u2550O)\u2014, H2N\u2014C(\u2550O)\u2014, (C1-4-alkyl)HN\u2014C(\u2550O)\u2014, (C1-4-alkyl)2N\u2014C(\u2550O)\u2014, aryl, aryl-C1-3-alkyl-, aryl-C1-3-alkyl-O\u2014, heterocyclyl, heterocyclyl-O\u2014, heterocyclyl-C1-3-alkyl-O\u2014, heteroaryl, heteroaryl-C1-3-alkyl- and heteroaryl-C1-3-alkyl-O\u2014,
wherein each alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from F, OH and C1-4-alkyl-O\u2014, and
wherein each heterocyclyl is optionally substituted with one or more C1-3-alkyl;
Ar2 is selected from a group consisting of:
phenylene and a 5- or 6-membered monocyclic heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O, or S,
wherein all of the before mentioned groups may be optionally substituted with one or more substituents RA;
R2a and R2b are each independently selected from a group consisting of:
H and C1-3-alkyl;
R3 is selected from a group consisting of: H and C1-4-alkyl; and
R4 is selected from a group consisting of:
H, C1-6-alkyl, C3-10-carbocyclyl, C3-10-carbocyclyl-C1-3-alkyl-, C2-6-alkenyl, O2-6-alkynyl, C1-6-alkyl-O\u2014, RN1RN2N, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl and heteroaryl-C1-3-alkyl,
wherein in each carbocyclyl and heterocyclyl a \u2014CH2\u2014 group may optionally be replaced by \u2014C(\u2550O)\u2014, and
wherein each alkyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group may be optionally substituted with one or more substituents independently selected from the group R5; while
RN1 is selected from a group consisting of:
H and C1-4-alkyl;
wherein each alkyl group may be optionally substituted with one R5;
RN2 is selected from a group consisting of:
H, C1-4-alkyl, C3-10-carbocyclyl, C3-10-carbocyclyl-C1-3-alkyl, C2-6-alkenyl, C2-6-alkynyl, heterocyclyl, heterocyclyl-C1-3-alkyl, aryl, aryl-C1-3-alkyl, heteroaryl and heteroaryl-C1-3-alkyl,
wherein each carbocyclyl and heterocyclyl may be optionally substituted with one or more C1-4-alkyl, aryl or aryl-C1-3-alkyl-, and
wherein in each carbocyclyl and heterocyclyl a CH2\u2014 group may optionally be replaced by \u2014C(\u2550O)\u2014; and
with the provision that there is at least one CH2\u2014 group between any double or triple bond of the alkenyl and alkynyl groups and the nitrogen atom to which they are attached and
R5 is selected from a group consisting of:
F, Cl, Br, CN, OH, C1-4-alkyl-, C1-4-alkyl-O\u2014, C1-4-alkyl-S\u2014, C1-4-alkyl-S(\u2550O)2\u2014, H2N\u2014, (C1-4-alkyl)NH\u2014, (C1-4-alkyl)2N\u2014, C1-4-alkyl-(C\u2550O)\u2014NH\u2014, heterocyclyl and aryl,
wherein each alkyl may be optionally substituted with one or more F-atoms andor with a substituent selected from OH, C1-3-alkyl-O\u2014 and CN; and
wherein two substituents R5 attached to an aryl or heteroaryl group may be linked to each other and form a C2-5-alkylene bridging group in which one or two \u2014CH2\u2014 groups may be replaced by a group independently of each other selected from O, S, NH and N(C1-4-alkyl)-, wherein the C2-5-alkylene bridging group is optionally be substituted by one or two C1-3-alkyl groups or F atoms;
or a tautormer or pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein
R2a is H;
R2b is CH3; and
R3 is H.
3. A compound according to claim 1, wherein Ar2 is
4. A compound according to claim 1, wherein Ar1 is selected from a group consisting of:
phenylene, pyridinylene, pyrimidinylene, benzofuranylene and benzo1,3dioxolylene,
wherein each of the beforementioned groups may be substituted with one or two substituents RA.
5. A compound according to claim 1, wherein RA is F or Cl.
6. A compound according to claim 1, wherein R1 is selected from a group consisting of:
H, C1-4-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-O\u2014, tetrahydrofuranyl-O\u2014, C3-6-cycloalkyl-CH2\u2014O\u2014, (C1-4-alkyl)NH\u2014, (C1-4-alkyl)2N\u2014, phenyl, benzyl, phenyl-CH2\u2014O\u2014, piperidinyl, morpholinyl, pyrrolidinyl and pyrrolyl,
wherein each alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from F, OH and \u2014O\u2014CH3, and
wherein piperidinyl is optionally substituted with one or two CH3.
7. A compound according to claim 1, wherein
R4 is selected from a group consisting of:
H, C1-4-alkyl, C3-6-cycloalkyl, C4-6-cycloalkenyl, C3-6-cycloalkyl-C1-3-alkyl-, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkyl-O\u2014, RN1RN2N\u2014, heterocyclyl, heterocyclyl-C1-3-alkyl-, phenyl, phenyl-C1-3-alkyl-, heteroaryl and heteroaryl-C1-3-alkyl-,
wherein RN1 is selected from the group consisting of: H and O1-3-alkyl; and
wherein RN2 is selected from the group consisting of: H, C1-4-alkyl, O3-7-cycloalkyl and heteroaryl; and
wherein in each cycloalkyl and heterocyclyl a \u2014CH2\u2014 group may optionally be replaced by \u2014C(\u2550O)\u2014, and
wherein each alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl group may be optionally substituted with one to three substituents independently selected from the group consisting of: F, Cl, CN, OH, CF3, C1-3-alkyl, \u2014O\u2014(C1-3-alkyl) and \u2014NH\u2014(C\u2550O)\u2014O1-3-alkyl; and
wherein each heterocyclyl is selected from the group consisting of: azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, morpholinyl and 3H-pyrimidin-4-onyl; and
wherein each heteroaryl is selected from the group consisting of: pyrrolyl, furanyl, furazanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl.
8. A compound according to claim 1, wherein
Ar1 is selected from a group consisting of:
wherein the asterisk to the right side of each group indicates the bond which is connected to the azetidine ring of the core structure of the formula (I), and the asterisk to the left side of each group indicates the bond which is connected to a substituent R1, and in addition each of the before mentioned groups is optionally substituted with one or two F or Cl atoms;
R1 is selected from a group consisting of:
C1-4-alkyl, C1-4-alkyl-O\u2014, C3-5-cycloalkyl, C3-5-cycloalkyl-O\u2014, tetrahydrofuranyl-O\u2014, C3-5-cycloalkyl-CH2\u2014O\u2014, (C1-4-alkyl)2N\u2014, phenyl, benzyl, phenyl-CH2\u2014O\u2014, piperidinyl, morpholinyl, pyrrolidinyl and pyrrolyl,
wherein each alkyl and cycloalkyl may be optionally substituted with one to three F atoms or one OH or \u2014O\u2014CH3, and
wherein piperidinyl is optionally substituted with one CH3;
Ar2 is
R2a is H;
R2b is CH3;
R3 is H; and
R4 is selected from a group consisting of:
C3-5-cycloalkyl, cyclopentenyl, C3-5-cycloalkyl-CH2\u2014, C3-5-alkenyl, O3-6-alkynyl, RN1RN2N\u2014, heterocyclyl, phenyl, heteroaryl and heteroaryl-CH2\u2014,
wherein RN1 is selected from the group consisting of: H and CH3; and
wherein RN2 is selected from the group consisting of: H, cyclopropyl, pyridinyl and pyrimidinyl; and
wherein in each heterocyclyl a \u2014CH2\u2014 group may optionally be replaced by \u2014C(\u2550O)\u2014, and
wherein each alkyl, cycloalkyl, heterocyclyl and heteroaryl group may be optionally substituted with one to three F atoms andor with one or two substituents independently selected from the group consisting of: Cl, CN, OH, CF3, CH3, \u2014O\u2014CH3 and \u2014NH\u2014(C\u2550O)\u2014CH3; and
wherein each heterocyclyl is selected from the group consisting of: azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl and 3H-pyrimidin-4-onyl; and
wherein each heteroaryl is selected from the group consisting of: pyrrolyl, furanyl, furazanyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl and pyrimidinyl;
or a pharmaceutically acceptable salt thereof.
9. A compound according to claim 1, wherein
Ar1 is selected from a group consisting of:
\u2003which are each optionally substituted with one or two substituents independently selected from F and Cl;
R1 is selected from a group consisting of:
Ar2 is
R2a is H;
R2b is CH3;
R3 is H; and
R4 is selected from a group consisting of:
\u2014CH3, \u2014CH2CH3, \u2014CH2\u2014CH\u2550CH2, \u2014CF2\u2014CH3, \u2014CH2\u2014CF3, \u2014N(CH3)2,
or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 8 or 9, wherein
R1 is \u2014OCH2CH3.
11. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.
12. method for treating obesity, diabetes or dyslipidemia in a patient suffering from one of said conditions which method comprises administering to said patient a therapeutically effective amount of a compound according to claim 1.